International

Australia: $1 million in fines for 'false' health claims

Published

3 years ago

September 29, 2022

João Xabregas

Listen to this article

Reading Time: 2 minutes

Australia's drug regulator, the Therapeutic Goods Administration (TGA), has issued 73 infringement notices over claims by medical cannabis companies in their products that they could treat "serious diseases such as cancer and epilepsy". According to The Guardian Australia, three Australian cannabis drug companies, MGC Pharmaceuticals Ltd, cannatrek ltd and Little Green Pharma Ltd, were fined a collective $972.360 by the TGA for illegal advertising, both on their websites and social media platforms, where they claimed that the use of their products could help treat certain serious illnesses.

Although the scientific evidence is already considerable regarding the therapeutic potential of cannabis in diseases such as cancer or epilepsy, it should be noted that, in Australia, it is illegal to promote prescription drugs. The purpose of the law is to protect consumers from false and/or misleading claims about its effects, to ensure that proper medical advice comes only from healthcare professionals who have actually seen patients and know their medical histories.

"Furthermore, some of the advertising allegedly suggested or implied that certain medicinal cannabis products were recommended or approved by a government authority," the TGA said in a statement, quoted by The Guardian of Australia.

"Using claims about a serious illness or condition in advertising is also illegal without express authorization from the TGA, because Australians facing a serious illness or condition are a particularly vulnerable consumer group."

Professor Karen Price, president of the Royal Australian College of General Practitioners, said that cannabis for medical purposes is sometimes prescribed as a “medicine of last resort for specific diseases” and that, depending on the medical condition, “the quality of evidence varies. and in some cases it is inconclusive or insufficient to suggest any benefit to patients,” he said.

As for the companies targeted by fines, only MGC Pharmaceuticals, which is also based in Europe and currently has its website under maintenance, said in a statement that it had “fully cooperated with TGA to remedy the issues raised, including the removal of all publications of concern from its media channels, some of which were third-party publications, and the placing of the company's website under maintenance”. The company added that “the website will be online again in November, after the rebranding, with new internal guidelines implemented, to avoid repeating the occurrence”, tells The Guardian. The full article can be read on this link.

____________________________________________________________________________________________________

[Disclaimer: Please note that this text was originally written in Portuguese and is translated into English and other languages using an automatic translator. Some words may differ from the original and typos or errors may occur in other languages.]

____________________________________________________________________________________________________

What do you do with €3 a month? Become one of our Patrons! If you believe that independent cannabis journalism is necessary, subscribe to one of the levels of our Patreon account and you will have access to unique gifts and exclusive content. If there are many of us, we can make a difference with little!

João Xabregas

With a professional background in CAD technical drawing (2D and 3D), João Xabregas is an activist and advocate for all uses and applications of cannabis. He discovered and entered the world of cannabis during his youth, where he developed a special interest in the cultivation of the plant, which led him on a journey of self-learning through the world of cannabis that continues to this day. His adventures linked to cannabis cultivation began with the same goal as many others: to be able to guarantee the quality and eliminate any possible risks to his health of what he consumed, as well as to avoid any type of dependence on the illicit market. However, he quickly began to view the world of cannabis and everything related to it with a very different perspective. He admits the enormous passion he has for the most persecuted plant in the world and about which he is always willing to write and have a good conversation.